Multi‐target angiogenesis inhibitor combined with <scp>PD</scp>‐1 inhibitors may benefit advanced non‐small cell lung cancer patients in late line after failure of <scp>EGFR‐TKI</scp> therapy

Lian Yu, Runbo Zhong, Jinjing Xia et al.|International Journal of Cancer|2023

Cited by 25